Errata

The May 10, 2018, article by Armand et al, entitled “Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial” (*J Clin Oncol* [10.1200/JCO.2017.76.0793](https://doi.org/10.1200/JCO.2017.76.0793)), was published with an error.

After publication, the authors have chosen a **CC-BY-NC-ND open access license**.

This has been corrected as of August 3, 2018. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.2018.79.3547>; published September 10, 2018

The August 1, 2018, article by Cheson et al, entitled “Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study” (*J Clin Oncol* [10.1200/JCO.2017.76.3656](https://doi.org/10.1200/JCO.2017.76.3656)), was published without an Open Access license.

The Gold CC-BY-NC-ND Open Access license has since been added and should now appear online.

This has been corrected as of August 1, 2018.

DOI: <https://doi.org/10.1200/JCO.18.00995>; published September 10, 2018

Follow ASCO Journals on Twitter

@JCO_ASCO

@JOP_ASCO

@JGO_ASCO